Universitair Medisch Centrum Utrecht — Sponsor Intelligence | 37 EU Trials

Filter these 37 trials by condition, phase, country and more.

Open in Search →

37 Registered trials

17 Recruiting

14 Completed trials

15 Countries active

103 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III/IV

Phase IV

Phase I (Other)

Phase III: 12 Phase II: 8 Phase I/II: 1 Phase III/IV: 5 Phase IV: 5 Phase I: 1 Phase I (Other): 4 Phase I (FiH): 1

Oversight events:

3 serious breaches 1 temporary halt 1 unexpected event 1 corrective measure across 5 trials

View oversight register →

100%

14 of 14 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Colorectal cancer metastatic 2 Peripheral artery surgery 1 Schizophrenia 1 Brain injury 1 Endometrial cancer stage II 1 Peripheral artery stenosis 1 Schizoaffective disorder 1 Squamous cell carcinoma of the oral cavity 1 Endometrial cancer stage I 1 Pseudoxanthoma elasticum 1 Sjogren's syndrome 1 Peripheral artery restenosis 1

Top IMPs

ETIDRONATE DISODIUM 2 ACETYLSALICYLIC ACID 1 ALLOPURINOL SODIUM 1 ANAKINRA 1 ANGIOTENSIN II 1 AUTOLOGOUS CHONDROCYTES, REMESTEMCEL 1 BINIMETINIB 1 CANNABIDIOL 1 CISPLATIN 1 CLOPIDOGREL 1 DARBEPOETIN ALFA 1 DRONABINOL, CANNABIDIOL 1

All trials — page 2

37 total

Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended

2023-507889-89-00 Phase III 13 countries
Sentinel lymph node (SLN) detection in early oral cancer using Gallium-68-Tilmanocept PET/CT. Suspended

2025-521682-27-00 Phase III/IV 1 country
Randomized controlled trial comparing clinical outcomes of Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT) for… Ended

2024-514612-27-01 Phase III 1 country AUTOLOGOUS CHONDROCYTES, REMESTEMCEL
SENtinel lymph node mapping with GAllium-68-tilmanocept PET/CT in high/high- intermediate risk endometrial cancer: a proof-of-concept study Ended

2024-516708-40-00 Phase III 1 country
Safety of TEG001 in patients with r/r AML/high-risk MDS or r/r MM Ended

2024-517381-42-00 Phase I 1 country
Understanding the Neurobiology of Pharmacologically-induced Acute Stress on Ethical Decisions Ended

2023-508731-31-01 Phase IV 1 country HYDROCORTISONE; YOHIMBINE HYDROCHLORIDE
IPAD Trial Ended

2024-513124-41-00 Phase III 1 country HUMAN NORMAL IMMUNOGLOBULIN; HUMAN NORMAL IMMUNOGLOBULIN (IV)
RepurpSS-II study Ended

2024-510904-36-00 Phase II 1 country HYDROXYCHLOROQUINE SULFATE; LEFLUNOMIDE
The bilateral sentinel node detection rate of fluorescent indocyanine green compared to 99mTc and blue dye inthe sentinel node procedure in … Ended

2024-511966-36-00 Phase III/IV 1 country
A dose-esalation phase I/II study in patients with RAS-mutated metastatic colorectal cancer to investigate safety and clinical actvitiy of t… Ended

2023-509732-25-00 Phase I (FiH) 1 country BINIMETINIB; LAPATINIB; VINORELBINE
Combining drug-eluting bead chemoembolization and radioembolization for treatment of colorectal liver metastases: DEBIR90Y study Ended

2024-514767-26-00 Phase I (Other) 1 country
TOFA-PREDICT Ended

2024-510903-12-00 Phase IV 1 country ETANERCEPT; FOLIC ACID, ANHYDROUS; METHOTREXATE; METHOTREXATE DISODIUM; TOFACITI…
Inhibition of Mast cell Activation in AtheroScleroTic lesions using an Anti-IgE antibody approach (MAST) Ended

2024-513581-19-00 Phase III/IV 1 country OMALIZUMAB

Showing 25–37 of 37 trials

← All sponsors A–Z